Cerulean Pharma (DARE) Earning Somewhat Favorable Press Coverage, Analysis Finds
Headlines about Cerulean Pharma (NASDAQ:DARE) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerulean Pharma earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.4896842309325 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Cerulean Pharma (DARE) remained flat at $3.18 on Friday. 5,899 shares of the company’s stock traded hands. The firm’s market cap is $9.23 million. The company’s 50-day moving average price is $3.27 and its 200 day moving average price is $6.55. Cerulean Pharma has a 1-year low of $2.63 and a 1-year high of $35.80.
Separately, ValuEngine lowered Cerulean Pharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.
TRADEMARK VIOLATION NOTICE: “Cerulean Pharma (DARE) Earning Somewhat Favorable Press Coverage, Analysis Finds” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/08/cerulean-pharma-dare-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Cerulean Pharma Company Profile
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Stock Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related stocks with our FREE daily email newsletter.